Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals reports a Schedule 13G showing Janus Henderson Group plc beneficial ownership of 2,240,963 shares of Common Stock as of 03/31/2026. The filing states this position represents 5.3% of the class and that the Asset Managers exercise shared voting and dispositive power on behalf of managed client accounts.
The filing clarifies the Asset Managers generally exercise investment and voting discretion for Managed Portfolios and disclaim rights to receive dividends or sale proceeds tied to those accounts.
Tarsus Pharmaceuticals, Inc. Schedule 13G/A amendment reports that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin each beneficially own 3,600,000 shares of Common Stock, representing 8.46%, as of March 31, 2026.
The filing states the beneficial ownership percentages are calculated using 42,557,492 shares outstanding as of February 17, 2026 per the issuer's 10-K. The filing is a joint statement by the reporting persons and identifies Deep Track Capital, LP as the relevant entity for control relationships.
Prudential Financial, Inc. filed an Amendment No. 20 on Schedule 13G/A reporting beneficial ownership of 1,836,321 shares of Common Stock of Tarsus Pharmaceuticals, Inc. (4.3%) as of 03/31/2026. The filing shows shared voting power of 1,670,648 and shared dispositive power of 1,836,321. The disclosure attributes holdings to subsidiaries, including Jennison Associates LLC: 1,712,124 shares (4.0%), The Prudential Insurance Company of America: 117,972 shares (0.3%), and PGIM Quantitative Solutions LLC: 6,225 shares.
TARSUS PHARMACEUTICALS INC Schedule 13G/A amendment reports that Jennison Associates LLC beneficially owns 1,712,124 shares of common stock, representing 4.0% of the class. The filing lists sole voting power for 1,712,124 shares and shared dispositive power for 1,712,124 shares.
Tarsus Pharmaceuticals reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Total revenue reached $162.1 million, driven by $145.4 million in XDEMVY product sales and $16.7 million of license and collaboration revenue.
Operating expenses rose to $168.2 million, mainly from higher selling, general and administrative and R&D spending. Net loss narrowed to $7.0 million, or $0.16 per share, compared with a $25.1 million loss a year earlier. Cash, cash equivalents and marketable securities totaled over $388 million, and management believes existing capital will fund operations for at least 12 months, though additional financing may still be needed as the company scales commercialization and advances its pipeline.
Tarsus Pharmaceuticals reported strong first quarter 2026 growth driven by XDEMVY. Net product sales were $145.4 million, more than 85% higher than a year earlier, and total revenue reached about $162.1 million including $16.7 million of license and collaboration revenue from a China milestone.
The company reaffirmed full-year 2026 XDEMVY net product sales guidance of $670–700 million and continues to highlight peak sales potential exceeding $2 billion. Operating expenses rose as Tarsus invested heavily in commercialization and R&D, yet net loss narrowed to $7.0 million, or $(0.16) per share.
Cash, cash equivalents and marketable securities totaled $388.7 million as of March 31, 2026, supporting a pipeline that includes Phase 2 programs for ocular rosacea (TP-04) and Lyme disease prevention (TP-05), with topline data from both expected in the first half of 2027.
Tarsus Pharmaceuticals, Inc. director David E. I. Pyott acquired common stock through equity compensation rather than open‑market trading. On April 24, 2026, 1,383 shares of common stock were issued upon settlement of vested Restricted Stock Units (RSUs), with each RSU converting into one share.
The RSUs vested in full on that date, subject to his continuous service. Following these transactions, he holds 1,383 shares directly and 7,991 shares indirectly through the David E.I. Pyott Trust.
Tarsus Pharmaceuticals, Inc. filed its Form 10-K for the fiscal year ended December 31, 2025 describing its commercial launch and continued development programs.
The company reported net product sales of $451.4M for 2025 and delivered approximately 400,000 bottles during the year; launch-to-date net product sales are reported at $646M. The company notes an aggregate market value of common equity held by non-affiliates of approximately $1.7B as of June 30, 2025, and 42,557,492 shares outstanding as of February 17, 2026.
The report summarizes commercialization progress for XDEMVY (lotilaner ophthalmic solution) 0.25% (FDA approved July 2023, launched August 2023), ongoing clinical programs for TP-04 (ocular rosacea) and TP-05 (Lyme disease prophylaxis), license arrangements with Elanco and GrandPharma, manufacturing reliance on CMOs, and key risks including continued losses, supply dependencies, and reimbursement and market adoption uncertainties.
Tarsus Pharmaceuticals, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 25, 2026. Investors will elect four Class III directors to serve until 2029, cast an advisory vote on executive compensation, and ratify Ernst & Young LLP as independent auditor for 2026.
The proxy explains how to attend and vote online and confirms 43,023,959 common shares were outstanding on April 27, 2026. It also outlines board structure, committee memberships, director pay, and a pay-for-performance program for executives, including cash bonuses funded at 108% of target and expanded use of stock options, RSUs, and new performance-based RSUs.